Literature DB >> 12539076

Primary cutaneous cryptococcosis: a distinct clinical entity.

Ségolène Neuville1, Françoise Dromer, Odile Morin, Bertrand Dupont, Olivier Ronin, Olivier Lortholary.   

Abstract

Cryptococcus neoformans is an encapsulated yeast responsible for disseminated meningitis in immunocompromised hosts. Controversies persist on the existence of primary cutaneous cryptococcosis (PCC) versus cutaneous cryptococcosis being only secondary to hematogenous dissemination. Thus, we reviewed cryptococcosis cases associated with skin lesions reported in the French National Registry. Patients with PCC (n=28) differed significantly from those with secondary cutaneous cryptococcosis (n=80) or other forms of the disease (n=1866) by living area (mostly rural), age (older), ratio of men to women (approximately 1:1), and the lack of underlying disease. Evidence of PCC included the absence of dissemination and, predominantly, a solitary skin lesion on unclothed areas presenting as a whitlow or phlegmon, a history of skin injury, participation in outdoor activities, or exposure to bird droppings, and isolation of C. neoformans serotype D. Therefore, PCC is a distinct epidemiological and clinical entity with a favorable prognosis even for immunocompromised hosts.

Entities:  

Mesh:

Year:  2003        PMID: 12539076     DOI: 10.1086/345956

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  39 in total

1.  Primary cutaneous cryptococcosis in a liver transplant recipient.

Authors:  Tristan Ferry; Doriane Moos; Sylvie Radenne; Anne-Lise Bienvenu; Jean Kanitakis
Journal:  BMJ Case Rep       Date:  2011-06-17

2.  Surgical Management of Primary Cutaneous Cryptococcosis after Failed Medical Management.

Authors:  Justin Leigh McKinney; Dean Cerio; Cyrus Loghmanee; Paulo Pinho; Rui Gomes; Mili Patel; Janeen Miraglia; Manal Youssef-Bessler; Jonathan Zippin; Harini Rao
Journal:  J Hand Microsurg       Date:  2014-01-28

3.  Cryptococcal panniculitis in a renal transplant recipient: case report and review of literature.

Authors:  Sunil K Kothiwala; Mahesh Prajapat; Chhitar Mal Kuldeep; Arpita Jindal
Journal:  J Dermatol Case Rep       Date:  2015-09-30

4.  Mycobacterium chelonae hand infection after steroid injection in a patient with rheumatoid arthritis receiving long-term linezolid therapy.

Authors:  Jens Steen Olesen; Mikala Wang; Christian Wejse
Journal:  BMJ Case Rep       Date:  2017-01-30

Review 5.  Systemic Review of Published Reports on Primary Cutaneous Cryptococcosis in Immunocompetent Patients.

Authors:  Lin Du; Yali Yang; Julin Gu; Jianghan Chen; Wanqing Liao; Yuanjie Zhu
Journal:  Mycopathologia       Date:  2015-03-04       Impact factor: 2.574

6.  Presence of C. albidus, C. laurentii and C. uniguttulatus in crop and droppings of pigeon lofts (Columba livia).

Authors:  I Rosario; G Soro; S Déniz; O Ferrer; F Acosta; D Padilla; B Acosta
Journal:  Mycopathologia       Date:  2009-12-10       Impact factor: 2.574

Review 7.  Approach to the Solid Organ Transplant Patient with Suspected Fungal Infection.

Authors:  Judith A Anesi; John W Baddley
Journal:  Infect Dis Clin North Am       Date:  2015-12-28       Impact factor: 5.982

Review 8.  Cryptococcosis in solid organ transplant recipients: current state of the science.

Authors:  Nina Singh; Francoise Dromer; John R Perfect; Olivier Lortholary
Journal:  Clin Infect Dis       Date:  2008-11-15       Impact factor: 9.079

9.  Subcutaneous cryptococcosis due to Cryptococcus diffluens in a patient with sporotrichoid lesions case report, features of the case isolate and in vitro antifungal susceptibilities.

Authors:  A Serda Kantarcioğlu; Teun Boekhout; G Sybren De Hoog; Bart Theelen; Ayhan Yücel; Tuba R Ekmekci; Bettina C Fries; Reiko Ikeda; Adem Koslu; Kemal Altas
Journal:  Med Mycol       Date:  2007-03       Impact factor: 4.076

Review 10.  Dormancy in Cryptococcus neoformans: 60 years of accumulating evidence.

Authors:  Alexandre Alanio
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.